Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists - 1 Mar 2017

Bach Timothy A, Zaiken Kathy

Abstract excerpt

PURPOSE: Outcomes with direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) genotypes 1-4 were determined. METHODS: A total of 360 patients at 36 clinical sites in Massachusetts with HCV genotypes 1-4 and a prescription for at least one DAA medication between May 2011 and October 2015 were included. The primary investigator completed a retrospective and concurrent chart review, and data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ambulatory Care
Share to Ambulatory Care Facilities

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to Hepatitis C, Chronic

Share to Ribavirin

Share to Sofosbuvir

Share to Treatment Outcome

Share to Viral Load

Source

Identifiers

PMID: 28213381
DOI: 10.2146/ajhp160567

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting.PMID 28213381Read ↗

Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.Semantic proximity Read ↗

Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.Semantic proximity Read ↗

HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens.Semantic proximity Read ↗

Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.Semantic proximity Read ↗

Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.Semantic proximity Read ↗

Chronic Hepatitis C Treatment with Direct-Acting Antiviral Agents in a Real-Life Setting.Semantic proximity Read ↗

Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.Semantic proximity Read ↗

Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.Semantic proximity Read ↗

Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.Semantic proximity Read ↗

Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.Semantic proximity Read ↗

Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.Semantic proximity Read ↗

Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.